{"name":"Turnstone Biologics, Corp.","slug":"turnstone-biologics-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBYRUZVQmw3V0xUUUd0ZzlnS01fVFE1MHBiOUV6MzQ0TS1nQmphU0cwMFlFdFdvWGlCcHJYVzVGdmQyMUY0Xzk4VktDR0hzNGNGT05aeGVmSnRjT1RDRnJ0dmlMUjlYcnFKeDBaT2VTaVU?oc=5","date":"2025-08-21","type":"trial","source":"Oncology Pipeline","summary":"Xoma buys a cheap Mural | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Xoma buys a cheap Mural | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOVEcwUWlVNWVfWG5OdWphVzNPYjRsa1liY3RaS2ozTkhmVjhuRE1lMzNfNFlWOGVhSkN5ZE5IbG9tQzJ5NUNpU2pxdWxValh3MHFlbl9BdUJ2U0VhS2YwTUVVaHlQYUc1Y01BTy0ydnlFaTh1TVEtbzFPMVV0VGgwQjJmdEdGVEtCTldVTS05cGU2SU1CVXdkLWFHdjBuVUMtNmY2aQ?oc=5","date":"2025-08-21","type":"deal","source":"Pharmaceutical Executive","summary":"XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction - Pharmaceutical Executive","headline":"XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQM3lyQ1oyOGtDRmRFdTVJTGJVM19uSG0taUo2TDQyM3UwNHlkUTd0Ulc2ZnAzRUpkNUROWGVqLWx6Nlp0QU9iX1hTSjVoNGo5WDZxNGRvazV3cE0yUkxka0V6aG5McWVPczl0WkdjVDZfSWlTUTVOaXZUUFAzX2s2bDBKRU1qSnNVUGtEQk9ZaDVNRVBkb09VbjM2WXozS24yNVpNd3N3VnFxOURPcmpLZ0RBbjlUeWZNRkRGZ01sZUJPVkdYWVBfSDcwWnBha29YU1NFSmFzQVR2U1JCX3NCcGF2QXRadw?oc=5","date":"2025-08-11","type":"pipeline","source":"Quiver Quantitative","summary":"XOMA Royalty Completes Tender Offer for Turnstone Biologics, Stockholders to Receive Cash and Contingent Value Right - Quiver Quantitative","headline":"XOMA Royalty Completes Tender Offer for Turnstone Biologics, Stockholders to Receive Cash and Contingent Value Right","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQaDJSdjlQbFc2WmkwYndMVHUwbl8tNFNuUk0wMlN3S1NyR0k0SUtxc0tpSGRtaHp6cV85Sk1pdmpxYVdZSUc0MTR1SzNfaVU0QS1oT1R1ZmRmb1BTMm1JVDkxZ2R1ZU5LYUtaclRrcjFDNlQxRTVpb0o2U1FhNWRYeWIwR2pBdWxvckUzWldhTmdBbWtOdlJRNHZJNUdCZ2hkX3phWkREWVctYjlJNUVmc3JlTC1uOE96QjFhVzQyQ0ZCQzZwZFR6SnBYczZ0ME9kUzJHWVJndk5yZlFEdGc?oc=5","date":"2025-08-11","type":"pipeline","source":"GlobeNewswire","summary":"XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - GlobeNewswire","headline":"XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPcWVMRlZOX1g0bWhVblRiVlNFd1JLdkVpVkp3Rllhc09UWXJ2aUVNU0k2NTVWTVRKVkE0dVBiOXFYNkpmOXd2Q2E1dlF4T0FTM2NwR0F1Q1VuVFB5cFpCem9lVkd3eEdVNmZkY3JZV1kzYnk4eERVM0FzellKcEN2U0ZpQ2JBZTRLYWNjR1R6QlRBUXN4RE80RFBKWTNwMnlhbTlvelNn?oc=5","date":"2025-07-15","type":"deal","source":"labiotech.eu","summary":"Are royalty deals moving up the biopharma funding ladder? - labiotech.eu","headline":"Are royalty deals moving up the biopharma funding ladder?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBPLUx0eGozZjNqUWhZejJmWHFyUDNLTHpIS0JTU3V0bmd5TnVIN1BpeFdfbEhzZU54d0JMWDhNTWRmU3hoWjhYLXdfTFdHMXdfMjdWQ2JMRjhkb0lLZFUyVmFOMmVQU0dDemZrSg?oc=5","date":"2025-07-15","type":"trial","source":"Oncology Pipeline","summary":"Essa succumbs to Xoma | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Essa succumbs to Xoma | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQcFRUdGJ1NE0zbXlVanptaDk4Z0FWYWpJbkRiRUtTeVV2TFlocUlKaThicFpfM2NPd0dCZ0ZBOVJHeDkwbk9GY1F3YjlyRjVnb1J5bzZRTEx5Z09pZHk1YTdBU2xPS3ZkQTJtVmxUcnlKQUxKaXMzM1BCUmVVbms5SlRiRWxoak5KMW9JbHNBeERUczJpR0UwZUlkVWotTS1XUHc?oc=5","date":"2025-06-27","type":"deal","source":"Fierce Biotech","summary":"Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout - Fierce Biotech","headline":"Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxOZnpVREdraHQ3WC0tQmFEMHRob0R6YkY3QUZMSi1LYnBISmZ5OWlSdWlEQVN1bHY4ZjQ3YmVScXZ6OHY2UjVuRUNKXzUzWmRCeHdPTkNqOWE5ZkpnZXJ2UkpGcHFWWnFWTjB0QVR3N2xwOFRyRnNvYW9QUHVtZzlZc0hDSVVFbC1EUXN2TmsxNGNoY3FQWXpCTy1ZZUdJS3NwcC10UmtmUzNKNVF6S2k4R1A2REU3UGVFUjZKV2ZtM3BReklPOW5od205bkU4SWoxMktWR0g1YWgxT3o5ZkNGRUNtNmJ4a0l2eFBrcmJHSUNjS0p3OFRSMUxjMVdZSGRUdmJoV0NSYmsxS0RjTUR4czJnbUVfV1lrSm9YaVQtUlNrb2FnRlJDbW9URF83R3p0ZmN5SlFtdUc4Z3I4MkJDYWR6OA?oc=5","date":"2025-06-27","type":"pipeline","source":"GlobeNewswire","summary":"Turnstone Biologics Corp. Enters into Agreement to be - GlobeNewswire","headline":"Turnstone Biologics Corp. Enters into Agreement to be","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5YekFueGwxc29qTkdNNk1RNnpuOHlQbjRINVlwQVpzcmZyc04yMFppMWpjWTNuWWJWSzZxUnZCNjhFVzYyRnk5SFRGYUQ5YjB4cGxr?oc=5","date":"2025-02-04","type":"pipeline","source":"FirstWord Pharma","summary":"Turnstone, Omega cut staff in separate struggles to stay afloat - FirstWord Pharma","headline":"Turnstone, Omega cut staff in separate struggles to stay afloat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxONFk3a0xVbGhGS2c4M2daemxmUklpNVRCa2xMZk94RXN6ZmFIN2JrNjNteWxTRDJ3RXZ4V3hxOTQ3M0h6NnBqRTh0MGNXcVhCeXdNcXRWM0sxZE54M3RFb1RzeExwbU1mZlZTeWpkZjZmS0tGX2RnbVdBYUdXX19VeERqcGc1TnMtTC1QT0lBaDYyVmNsUXRFY0hFVTdTSVFndVBTbTM5V3EwNGN4?oc=5","date":"2025-02-04","type":"regulatory","source":"Fierce Biotech","summary":"Turnstone ends last remaining clinical program due to costs, plots more layoffs - Fierce Biotech","headline":"Turnstone ends last remaining clinical program due to costs, plots more layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRFhBal83c24zUlp0OTRNOXRHUnNPSUFDdm9WeU9UQTNvYnp5OTRDRUhhOTEtWHdETHREaUlPMnBlanFhMUJMMTZWZmNZWWdtLVZpajBaY2tzZEV1TlRodlZ0dDFvbEgyZTJ6VGVyckFxQ25PTTFGTXdKNDROdUNIS0I1UGtYS3BwVFdn?oc=5","date":"2023-06-13","type":"pipeline","source":"BioPharma Dive","summary":"A cell therapy startup looks to an IPO to avert financial peril - BioPharma Dive","headline":"A cell therapy startup looks to an IPO to avert financial peril","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}